Auspherix and Domainex worked together to develop a novel class of gold(I) antibiotics, with a broad spectrum antibacterial activity against the so-called ESKAPE pathogens.
Drug Discovery Case Studies
Domainex has generated crystal structures, assays and a chemical library for lysine methyltransferases (KMTs), which are involved in epigenetic gene regulation
Domainex's lead programme targets key kinases (TBK1/IKKe) that have been validated as novel drug targets in inflammatory diseases such as psoriasis, rheumatoid arthritis, COPD
Using CDH technology, Domainex worked with UCB to develop the crystal structure of Mitogenactivated protein kinase kinase (MAPKK, MEK) for use in drug discovery.
Medicinal Chemists at Domainex collaborated with university researchers to develop novel inhibitors of a protease target, a potential treatment for asthma.
Using a peptidomimetic approach, Ark Therapeutics and Domainex have developed inhibitors of protein-protein interactions PPI targeting the NRP1 function.